Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt

Author's Department

Economics Department

All Authors

Magdy Abdelhamid, Gihan Hamdy Elsisi, Ahmed Seyam, Ahmed Shafie, Mary Kirollos, Sandy Emad, Shady Mansy, Mohamed Sobhy

Document Type

Research Article

Publication Date

3-14-2022

Abstract

In Egypt, cardiovascular (CV) diseases are not only the cause of 33% of disability-adjusted life years but are also a leading cause of death. This study aimed to evaluate dapagliflozin's cost-effectiveness as an add-on to the standard of care (SOC) for the treatment of heart failure with reduced ejection fraction (HF-rEF) from the Egyptian healthcare system perspective.

First Page

450

Last Page

456

This document is currently not available here.

Share

COinS